NAMs for Rare Diseases
Patient-derived cells and disease-in-a-dish models are revolutionizing rare disease research—creating hope for the 300 million people worldwide affected by over 7,000 rare conditions
Small Patient Populations
Too few patients for traditional clinical trials—some diseases affect only hundreds of people worldwide.
No Animal Models
Many rare genetic diseases have no natural animal equivalent—the mutations simply don't cause the same effects in mice.
Limited Commercial Interest
Small market size means less pharmaceutical investment, despite devastating patient impact.
Complex Genetics
80% of rare diseases are genetic, often involving multiple genes with varied mutations across patients.
Patient Sample
Collect blood or skin cells from patients with the rare disease
Create iPSCs
Reprogram cells into induced pluripotent stem cells
Differentiate
Turn iPSCs into the affected cell type (neurons, heart, liver)
Disease in a Dish
Cells show disease features—test drugs on the actual patient's cells
Rare Diseases Modeled with NAMs
Real conditions being studied with human-relevant approaches
Cystic Fibrosis
CFTR gene mutations cause thick mucus buildup. Patient-derived organoids now guide personalized treatment selection.
Huntington's Disease
CAG repeat expansion causes progressive neurodegeneration. iPSC-neurons show disease-specific pathology.
Duchenne Muscular Dystrophy
Dystrophin gene mutations cause progressive muscle weakness. iPSC-myocytes model disease progression.
Progeria (HGPS)
LMNA mutation causes rapid aging. iPSC-derived cells show premature aging phenotypes for drug testing.
Spinal Muscular Atrophy
SMN1 gene deficiency causes motor neuron loss. iPSC models helped develop first approved gene therapy.
Niemann-Pick Disease
Lipid metabolism disorder causing neurodegeneration. iPSC models reveal disease mechanisms in human cells.
Why NAMs Matter for Rare Diseases
Unique advantages for orphan drug development
Patient-Specific Models
Create disease models from actual patients when no animal model exists for the condition.
Capture Genetic Diversity
Model different mutations in the same gene that cause varying disease severity.
Reduce Trial Size Needs
In vitro screening helps identify patients most likely to respond, enabling smaller clinical trials.
Accelerate Development
Test drug candidates faster without waiting to establish animal models that may never work.
Personalized Treatment
Test which drugs work on individual patient's cells before prescribing treatment.
Biobank for Future
Create iPSC repositories that provide unlimited supply of patient cells for ongoing research.
Success Story: Cystic Fibrosis Organoids
Patient-derived intestinal organoids now guide treatment for cystic fibrosis patients. Doctors test which CFTR modulator drugs work on a patient's own organoids before prescribing. This approach has transformed CF treatment from trial-and-error to personalized precision medicine—all without animal testing and directly predicting human response.